Summary
Zoetis Inc. has announced key executive leadership changes effective November 1, 2022, designed to refine organizational structure and drive future growth. Glenn David will transition to a new role as Executive Vice President and Group President, U.S. Operations, Global Diagnostics and BioDevices, expanding his responsibilities to include critical U.S. markets and emerging technology areas. This move signals a strategic focus on these growth segments within the company. Concurrently, Jamie Brannan will assume the role of Executive Vice President and Group President, International Operations and Aquaculture (PHARMAQ), indicating continued emphasis on its global veterinary pharmaceutical business and the aquaculture sector. Wafaa Mamilli, Chief Digital and Technology Officer, will also take on additional oversight of China, Brazil, and Precision Animal Health, highlighting the company's commitment to digital transformation and expansion in key emerging markets. These appointments reflect Zoetis's proactive approach to leadership development and market strategy.
Key Highlights
- 1Key executive leadership transitions effective November 1, 2022.
- 2Glenn David appointed EVP & Group President, U.S. Operations, Global Diagnostics and BioDevices.
- 3Jamie Brannan appointed EVP & Group President, International Operations and Aquaculture (PHARMAQ).
- 4Wafaa Mamilli to expand oversight to China, Brazil, and Precision Animal Health.
- 5The changes indicate a strategic realignment of responsibilities to focus on key growth areas and markets.
- 6No changes in overall officer compensation were disclosed in this filing.